| Peter Jorgenson, PMHNP | |
|
1519 S Phillips St, Algona, IA 50511-3649 | |
| (515) 295-2451 | |
| Not Available |
| Full Name | Peter Jorgenson |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner - Psychiatric/mental Health |
| Location | 1519 S Phillips St, Algona, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518667997 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | G173416 (Iowa) | Primary |
| Entity Name | Kossuth Regional Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184636557 PECOS PAC ID: 3375454259 Enrollment ID: O20040319000696 |
News Archive
A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis can achieve survival rates as high as 84 percent-a full 15 percent improvement over the previous clinical trial in this series.
Genentech, a member of the Roche Group, today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil.
As U.S. Latinos face a staggering 142% projected rise in cancer cases by 2030, UT Health San Antonio leaders gathered international cancer experts to publish a new book with innovative research and recommendations to reduce Latino cancer.
Hospital patients admitted with malnutrition or who don't eat for several days are at greater risk of a prolonged hospital stay, according to a study published in CMAJ.
Intrauterine devices (IUDs) may protect against cervical cancer. This is the conclusion of the broadest epidemiological study to date in which has participated the research group in Viruses and Cancer of IDIBELL, published at The Lancet Oncology.
› Verified 9 days ago
| Entity Name | Steven Slye |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114678141 PECOS PAC ID: 1254718398 Enrollment ID: O20220511002113 |
News Archive
A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis can achieve survival rates as high as 84 percent-a full 15 percent improvement over the previous clinical trial in this series.
Genentech, a member of the Roche Group, today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil.
As U.S. Latinos face a staggering 142% projected rise in cancer cases by 2030, UT Health San Antonio leaders gathered international cancer experts to publish a new book with innovative research and recommendations to reduce Latino cancer.
Hospital patients admitted with malnutrition or who don't eat for several days are at greater risk of a prolonged hospital stay, according to a study published in CMAJ.
Intrauterine devices (IUDs) may protect against cervical cancer. This is the conclusion of the broadest epidemiological study to date in which has participated the research group in Viruses and Cancer of IDIBELL, published at The Lancet Oncology.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter Jorgenson, PMHNP 1519 S Phillips St, Algona, IA 50511-3649 Ph: () - | Peter Jorgenson, PMHNP 1519 S Phillips St, Algona, IA 50511-3649 Ph: (515) 295-2451 |
News Archive
A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis can achieve survival rates as high as 84 percent-a full 15 percent improvement over the previous clinical trial in this series.
Genentech, a member of the Roche Group, today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil.
As U.S. Latinos face a staggering 142% projected rise in cancer cases by 2030, UT Health San Antonio leaders gathered international cancer experts to publish a new book with innovative research and recommendations to reduce Latino cancer.
Hospital patients admitted with malnutrition or who don't eat for several days are at greater risk of a prolonged hospital stay, according to a study published in CMAJ.
Intrauterine devices (IUDs) may protect against cervical cancer. This is the conclusion of the broadest epidemiological study to date in which has participated the research group in Viruses and Cancer of IDIBELL, published at The Lancet Oncology.
› Verified 9 days ago